Médias
Documents
Three-Year Follow-Up Data for SPRYCEL®▼ (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase
Documents
ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Aucun résultat à afficher.
Collection
{{collectionTitle}}
Collection
{{collectionTitle}}
Collection
{{collectionTitle}}
{{productIsPremium}}
{{productCategoryLabel}}
{{productTitle}}
{{productIsPremium}}
{{productCategoryLabel}}
{{productThemeLabel}}
{{productTitle}}
{{productPages}}
{{productLanguageIsoCode}}
{{sortLabel}}
{{sortLabel}}